Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies.
Dockendorff C, Nagiec MM, Weïwer M, Buhrlage S, Ting A, Nag PP, Germain A, Kim HJ, Youngsaye W, Scherer C, Bennion M, Xue L, Stanton BZ, Lewis TA, Macpherson L, Palmer M, Foley MA, Perez JR, Schreiber SL. Dockendorff C, et al. Among authors: buhrlage s. ACS Med Chem Lett. 2012 Oct 11;3(10):808-813. doi: 10.1021/ml300172p. Epub 2012 Aug 30. ACS Med Chem Lett. 2012. PMID: 23074541 Free PMC article.
Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates.
Youngsaye W, Vincent B, Hartland CL, Morgan BJ, Buhrlage SJ, Johnston S, Bittker JA, MacPherson L, Dandapani S, Palmer M, Whitesell L, Lindquist S, Schreiber SL, Munoz B. Youngsaye W, et al. Among authors: buhrlage sj. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5502-5. doi: 10.1016/j.bmcl.2011.06.105. Epub 2011 Jun 30. Bioorg Med Chem Lett. 2011. PMID: 21802942 Free PMC article.
Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).
Tan L, Nomanbhoy T, Gurbani D, Patricelli M, Hunter J, Geng J, Herhaus L, Zhang J, Pauls E, Ham Y, Choi HG, Xie T, Deng X, Buhrlage SJ, Sim T, Cohen P, Sapkota G, Westover KD, Gray NS. Tan L, et al. Among authors: buhrlage sj. J Med Chem. 2015 Jan 8;58(1):183-96. doi: 10.1021/jm500480k. Epub 2014 Jul 30. J Med Chem. 2015. PMID: 25075558 Free PMC article.
Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.
Schauer NJ, Magin RS, Liu X, Doherty LM, Buhrlage SJ. Schauer NJ, et al. Among authors: buhrlage sj. J Med Chem. 2020 Mar 26;63(6):2731-2750. doi: 10.1021/acs.jmedchem.9b01138. Epub 2019 Nov 20. J Med Chem. 2020. PMID: 31682427 Review.
Proteomics-Based Identification of DUB Substrates Using Selective Inhibitors.
Bushman JW, Donovan KA, Schauer NJ, Liu X, Hu W, Varca AC, Buhrlage SJ, Fischer ES. Bushman JW, et al. Among authors: buhrlage sj. Cell Chem Biol. 2021 Jan 21;28(1):78-87.e3. doi: 10.1016/j.chembiol.2020.09.005. Epub 2020 Oct 1. Cell Chem Biol. 2021. PMID: 33007217 Free PMC article.
Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion.
Harris IS, Endress JE, Coloff JL, Selfors LM, McBrayer SK, Rosenbluth JM, Takahashi N, Dhakal S, Koduri V, Oser MG, Schauer NJ, Doherty LM, Hong AL, Kang YP, Younger ST, Doench JG, Hahn WC, Buhrlage SJ, DeNicola GM, Kaelin WG Jr, Brugge JS. Harris IS, et al. Among authors: buhrlage sj. Cell Metab. 2019 May 7;29(5):1166-1181.e6. doi: 10.1016/j.cmet.2019.01.020. Epub 2019 Feb 21. Cell Metab. 2019. PMID: 30799286 Free PMC article.
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.
Yang J, Weisberg EL, Qi S, Ni W, Mei H, Wang Z, Meng C, Zhang S, Hou M, Qi Z, Wang A, Jiang Y, Jiang Z, Huang T, Liu Q, Magin RS, Doherty L, Wang W, Liu J, Buhrlage SJ, Liu Q, Griffin JD. Yang J, et al. Among authors: buhrlage sj. Leukemia. 2022 Apr;36(4):1048-1057. doi: 10.1038/s41375-021-01494-w. Epub 2022 Jan 17. Leukemia. 2022. PMID: 35034955
69 results